Mirum Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M |
| Selling, general & administrative | $257.0M | $202.2M | $145.9M | $89.1M | $59.2M |
| Research and development | $186.2M | $140.6M | $102.6M | $106.8M | $131.4M |
| Operating expenses | $543.4M | $424.5M | $295.5M | $208.3M | $192.6M |
| Operating income | -$22.1M | -$87.6M | -$109.2M | -$131.2M | -$173.4M |
| Interest expense | $14.4M | $14.3M | $15.1M | $16.0M | — |
| Pretax income | -$21.4M | -$86.9M | -$162.4M | -$142.1M | -$84.0M |
| Income tax expense | $1.9M | $1.0M | $991,000 | -$6.4M | $37,000 |
| Net income | -$23.4M | -$87.9M | -$163.4M | -$135.7M | -$84.0M |
| Balance Sheet | |||||
| Cash and equivalents | $296.7M | $222.5M | $286.3M | $28.0M | $31.3M |
| Current assets | $549.7M | $392.8M | $387.5M | $190.2M | $166.6M |
| Total assets | $842.8M | $670.8M | $646.6M | $352.9M | $294.7M |
| Current liabilities | $205.8M | $126.6M | $87.1M | $64.7M | $42.6M |
| Total liabilities | $528.1M | $445.1M | $398.0M | $210.9M | $174.4M |
| Stockholders' equity | $314.7M | $225.6M | $248.7M | $142.0M | $120.2M |
| Cash Flow Statement | |||||
| Cash from operations | $55.8M | $10.3M | -$70.9M | -$120.1M | -$132.8M |
| Depreciation and amortization | $24.2M | $23.6M | $10.8M | $3.2M | $595,000 |
| Stock-based compensation | $71.4M | $48.4M | $35.0M | $27.0M | $23.1M |
| Capital expenditure | $954,000 | $993,000 | $109,000 | $278,000 | $24,000 |
| Free cash flow | $54.9M | $9.3M | -$71.1M | -$120.4M | -$132.8M |
Shares outstanding 61.0M · Free float 90.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.